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There are two general paradigms for clinical drug develop-
ment. The first involves understanding a mechanism or
pathway leading to disease, identifying a target, screening
candidate drugs for target interaction, and then assessing
efficacy in animal models and ultimately in clinical trials.
This sequential process is time-consuming and expensive—
successful development of a new drug can take decades
and cost as much as $800 million (DiMasi et al, 2003).
Nevertheless, this approach has led to the development of
many successful drugs, such as those now used to treat
many patients with hypertension and hyperlipidemia. A
second, increasingly more common paradigm involves the
unapproved (off-label) use of a drug developed for a differ-
ent disease, such as use of imiquimod (initially developed to
treat genital warts) for actinic keratoses and keloids. In
some cases, an approved drug given to patients for one
disease is serendipitously noted to improve a second con-
dition in those patients, revealing a new target for drug ac-
tion or a similar target in another disease. Another example
is etanercept, which was initially used to treat rheumatoid
and psoriatic arthritis, and later found to be effective in
psoriasis (Goffe and Cather, 2003). This pathway to drug
discovery, although unpredictable, is usually much quicker,
since mechanistic studies and extensive screening of com-
pounds have been bypassed.
Imatinib mesylate (Gleevec, formerly known as STI571) is
a drug that has taken both paths. It was originally developed
by Novartis Pharmaceuticals as a specific inhibitor of the
BCR-ABL tyrosine kinase, which arises from an acquired
t(9;22) genetic translocation (Philadelphia chromosome) that
causes chronic myelogenous leukemia. The constitutive ty-
rosine kinase activity drives proliferation of malignant cells
and is sufficient to induce the disease (Daley et al, 1990).
Imatinib mesylate competes for the ATP-binding site on
BCR-ABL, disabling its kinase activity, and produces a com-
plete hematologic response in most patients (Druker et al,
2001). Inhibition of additional protein tyrosine kinases (PTK),
c-kit, and the platelet-derived growth factor (PDGF) receptor
was also noted. Gastrointestinal stromal tumors often ex-
press mutated forms of c-kit, and patients with these tumors
were also found to respond to imatinib mesylate (van Ooste-
rom et al, 2001). When imatinib mesylate was found effective
in patients with the hypereosinophilic syndrome (Gleich et al,
2002), investigation into the genetic basis of this disease
revealed that many of these patients, as well as some with
systemic mastocytosis, harbor a chromosomal deletion that
gives rise to an oncogenic fusion protein (FIP1L1-PDGFRA)
involving the PDGF receptor (Cools et al, 2004). Imatinib
mesylate is thus now considered a first-line agent for many
malignancies characterized by aberrant PTK signaling via
ABL, c-kit, and PDGF receptor.
We desperately need new agents to treat patients with
advanced melanoma, and there is currently considerable
interest in imatinib mesylate. There are several reasons to
think that this drug may have therapeutic potential in me-
lanoma. First, it is known that PTK signaling is critical for
sustaining melanocyte proliferation in vitro and for migration
of melanocytic cells in vivo (Halaban, 2000). Binding of lig-
ands such as stem cell factor, hepatocyte growth factor,
and fibroblast growth factor to their cognate PTK receptors
on melanocytes triggers a phosphorylation cascade (mito-
gen-activated protein kinase pathway) that in turn activates
additional kinases (PI3 and Akt) that promote cell prolifer-
ation and survival. In addition, overexpression of some PTK
receptor ligands such as hepatocyte growth factor is asso-
ciated with increased susceptibility to melanoma in mice
(Noonan et al, 2001). All three known targets of imatinib
mesylate (ABL, c-kit, PDGF receptor) are generally ex-
pressed in melanoma, although c-kit expression tends to be
diminished in metastatic lesions (Shen et al, 2003).
Imatinib mesylate is currently being tested in patients
with metastatic melanoma, but preliminary results of Phase
II trials have not been very impressive. One trial involving 26
patients from Vanderbilt-Ingram Cancer Center and Beth
Israel Deaconess Medical Center did not produce any clin-
ical responses, but the course of treatment was limited in
most patients by drug toxicity.1 Data on expression of
known drug targets in tumors was not reported. A second
trial from MD Anderson Cancer Center was limited to 21
patients with biopsies demonstrating expression of relevant
PTK in over 25% of tumor cells.2 A near complete response
was seen in one patient with the strongest expression of
c-kit, but the remaining 20 patients experienced progressive
disease over 6–12 wk.1
There has been a concurrent effort in several laboratories
to evaluate imatinib mesylate in mouse models of localized
melanoma. In a recent issue of the Journal, McGary et al
(2004) employed a xenograft model in which human
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melanoma cells were implanted into immunodeficient mice
to form subcutaneous tumors. Two melanoma cell lines
were used: one line (A375SM) with strong expression of
PDGF receptor-a, weak expression of PDGF receptor-b,
and no expression of c-kit; and another (MeWo) with weak
expression of PDGF receptor-a, strong expression of PDGF
receptor-b and positive expression of c-kit. Following in-
jection of melanoma cells, mice received phosphate-buff-
ered saline or imatinib mesylate (100 mg per kg oral gavage
three times weekly). There was not a significant difference in
tumor growth (for either cell line) in mice that had received
drug versus the saline control. To confirm tumor delivery and
biological activity of the imatinib mesylate, the authors
demonstrated reduced PDGF receptor phosphorylation in
tumors from animals that received the drug. Potential ef-
fects of the drug on cultured cells were not examined.
In contrast to these results, Redondo et al (2004) in this
issue of the Journal use mouse (B16F10) melanoma cells to
establish subcutaneous tumors in syngeneic mice, and re-
port that imatinib mesylate inhibits tumor growth. Mice were
injected with B16F10 cells and simultaneously received in-
traperitoneal injections of saline or imatinib mesylate (37.5
mg per kg on 5 consecutive days per week for 2 wk). There
was a 77% reduction in tumor growth in animals receiving
drug compared with saline control. The results approached,
but did not achieve, statistical significance (p¼0.1), likely
due to the small numbers of animals used in the study. The
authors also demonstrate that addition of imatinib mesylate
to B16F10 cells in culture led to decreased proliferation that
was associated with a G1/S phase arrest but not apoptosis.
They were unable to detect c-kit expression in cultured
B16F10 cells or tumors, and did not assess expression of
ABL or PDGF receptor or their phosphorylation status.
There are several potential explanations to account for the
different activity of imatinib mesylate reported by these two
groups. First, imatinib mesylate could indeed have a limited
spectrum of activity—for B16F10 murine cells but not
A375SM, MeWo, or other human melanoma cells. Conceiv-
ably this drug, although developed against human PTK, may
target a molecule selectively expressed on these murine
melanoma cells. In addition, differences in drug metabolism
and transport in and out of the cells could dramatically affect
therapeutic responses. A second issue may relate to its ab-
sorption and bioavailability in each study. Although McGary
et al administered the drug by oral gavage, Redondo et al
used intraperitoneal injection. Although McGary et al
achieved sufficient tumor delivery to downregulate PDGF
receptor phosphorylation, orally administered drug may re-
sult in lower drug levels in blood and tumor compared with
the intraperitoneal route. Third, there may be a role for a host
immune response in the inhibition of tumor growth mediated
by imatinib mesylate. In the B16F10 model used by Redondo
et al, the tumors are syngeneic and the mice have a com-
petent immune system, whereas in the prior study by
McGary et al, the tumors are xenografts in immunodeficient
mice. It is possible that an immune response may facilitate
drug-induced tumor inhibition, although induction of specific
tumor cell immunity seems unlikely given the short-term
course of experiments by Redondo et al.
Multiple additional experiments need to be performed to
resolve these issues and to further clarify the potential ther-
apeutic effect of imatinib mesylate on melanoma in animal
models. Additional human melanoma lines should be ex-
amined in the xenograft model, using intraperitoneal drug
delivery. Effects on established tumors can be studied
by delaying administration of the drug until tumors have
formed. Tumors responding to drug should be examined
histologically to ascertain effects on proliferation and
apoptosis in vivo, as well as the presence and nature of a
host inflammatory response. If positive effects on estab-
lished tumors can be demonstrated, it would also be inter-
esting to examine whether the drug can protect against
tumor cell metastasis and animal survival. Should imatinib
mesylate prove to be a cytostatic agent, as suggested by
the results of Redondo et al showing a proliferation block
but not induction of apoptosis, it would be worthwhile to
investigate whether its efficacy can be enhanced by com-
bination with an adjuvant such as a cytotoxic drug or
proteosome inhibitor.
Preliminary results of Phase II trials in metastatic me-
lanoma (Wyman et al, 2003; Eton et al, 2004),2 as noted
above, have not been encouraging. Should addition of an-
other agent enhance efficacy in one of the mouse models,
then such combination therapy might be worth pursuing in a
clinical trial. If imatinib mesylate does prove to have activity
on melanoma cells as the report by Redondo et al may sug-
gest, it could still be useful as an adjuvant therapy in patients
with high-risk localized disease. These animal studies sug-
gest that c-kit and PDGF receptor are unlikely to be relevant
targets, given the absence of c-kit in B16F10 cells and
the lack of response to PDGF receptor dephosphorylation
(McGary et al, 2004). The initial target for which the drug was
developed, ABL, was not examined in these studies but re-
mains a possibility given its broad expression in human me-
lanomas (Shen et al, 2003). Given the highly conserved
enzymatic site in many PTK, and the presence of hundreds
of distinct PTK in cells, it seems plausible that other candi-
date targets exist. In fact, expression of several PTK has
been demonstrated in melanoma lines from different stages
of tumor progression but not in normal melanocytes (Easty
et al, 1995). Of note, the related PTK inhibitor gefitinib initially
appeared to benefit only 10% of patients with lung cancer,
but is now recognized to be particularly effective in patients
bearing particular mutations in epidermal growth factor re-
ceptor (Lynch et al, 2004). It is possible that a putative target
of imatinib mesylate in melanoma might similarly be ex-
pressed only on a subset of tumors. If such a target can be
defined in animal models, then conceivably those patients
with tumor expression of the target could be identified as
prime candidates for a future clinical trial.
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